tradmap

AVBP Earnings Arrivent Biopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$32 -$16 $0 2023 2024 2025
EPS
Net income (annual)
-$166M -$83M $0 2023 2024 2025
Net income
Return on equity (annual)
-54% -4% 45% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$25 -$12 $0 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26
EPS
Net income (quarterly)
-$64M -$32M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-32% -9% 14% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–14 of 14
Q2 20262026-06-30-2.012026-08-1210-Q
Q1 20262026-03-31-0.962026-05-1110-Q
FY 20252025-12-31-4.322026-03-0510-K
Q3 20252025-09-30-3.542025-11-1010-Q
Q2 20262025-06-30-2.782026-08-1210-Q
Q1 20262025-03-31-1.902026-05-1110-Q
FY 20252024-12-31-2.562026-03-0510-K
Q3 20252024-09-30-1.952025-11-1010-Q
Q2 20252024-06-30-1.342025-08-1110-Q
Q1 20252024-03-31-0.702025-05-1210-Q
FY 20242023-12-31-32.382025-03-0310-K
Q3 20242023-09-30-24.692024-11-1410-Q
Q2 20242023-06-30-20.602024-08-1410-Q
Q1 20242023-03-31-9.452024-05-0810-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.